| Literature DB >> 33911886 |
Bartholomeo Nicholaus Ngowi1, Bruno Sunguya2, Ayesiga Herman3, Alfred Chacha4, Eusebious Maro5, Leonard France Rugarabamu1, John Bartlett6, Emmanuel Balandya2, Kien Alfred Mteta1, Blandina Theophil Mmbaga6,7.
Abstract
BACKGROUND: Bacterial urinary tract infection (BUTI) is the commonest urinary tract infection among people living with human immunodeficiency virus (PLHIV). It causes significant morbidity in this vulnerable group. Immunosuppression due to HIV can mask the signs and symptoms of infection leading to asymptomatic disease. There is limited evidence in Tanzania regarding BUTI and PLHIV. This study aimed to determine the prevalence, etiology, risk factors and susceptibility pattern of isolates causing asymptomatic UTI in PLHIV at Kilimanjaro Christian Medical Centre (KCMC). PATIENTS AND METHODS: This cross-sectional study was conducted from July to September 2020 at Kilimanjaro Christian Medical Centre (KCMC) hospital. A questionnaire was used to collect social demographic data from patients' files together with necessary information required by this study. Urine samples were obtained from participants for urinalysis and urine culture and sensitivity. Data from 300 adults aged ≥18 years were analyzed using Statistical Package for Social Science (SPSS) version 22. Mean or median with their measure of dispersion were calculated for continuous variables. Logistic regression was used to determine associations between variables, where P-value <0.05 was considered to be significant.Entities:
Keywords: Tanzania; bacteria urinary tract infection; bacteriuria; multidrug resistance; people living with human immunodeficiency virus
Year: 2021 PMID: 33911886 PMCID: PMC8075732 DOI: 10.2147/IDR.S299776
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Characteristics of 300 Study Participants Living with HIV and Attending CTC Clinic at KCMC from July to September 2020
| Total | |
|---|---|
| Characteristics | n (%) |
| Age (years) (mean (SD) | 46.1 (11.9) |
| 18–40 | 103 (34.3) |
| >40 | 197 (65.7) |
| Male | 67 (22.3) |
| Female | 233 (77.7) |
| Single | 76 (25.3) |
| Married | 175 (58.3) |
| Widow | 39 (13.0) |
| Divorce/separated | 10 (3.3) |
| No | 285 (95.0) |
| Yes | 15 (5.0) |
| < 200 | 9 (3.0) |
| 200–500 | 80 (26.7) |
| > 500 | 211 (70.3) |
| No | 263 (87.7) |
| Yes | 37 (12.3) |
| Cloud | 26(8.7) |
| Clear | 274 (91.3) |
| Negative | 277 (92.3) |
| Positive | 23 (7.7) |
| Negative | 295 (98.3) |
| Positive | 5 (1.7) |
| < 20 | 218 (72.7) |
| 20–1000 | 73 (24.3) |
| >1000 | 9 (3.0) |
Prevalence and Risk Factors for UTI Among 300 Patients Living with HIV Attending CTC Clinic at KCMC from July to September 2020
| Factors | Urine Culture Result | ABU | ||||
|---|---|---|---|---|---|---|
| Negative | Positive | |||||
| n (%) | n (%) | |||||
| 263 (87.7) | 37(12.3) | COR (95% CI) | p-value | AOR (95% CI) | p-value | |
| 18–40 | 88 (85.4) | 15(14.6) | 1 | |||
| >40 | 175 (88.8) | 22(11.2) | 0.74(0.36; 1.49) | 0.397 | ||
| Male | 63 (94.0) | 4 (6.0) | 1 | 1 | ||
| Female | 200 (85.8) | 33 (14.2) | 2.59 (0.89; 7.62) | 0.082 | 2.35 (0.74; 7.54) | 0.148 |
| No | 250 (87.7) | 35 (12.2) | 1 | |||
| Yes | 13 (86.7) | 2 (13.3 | 1.09 (0.23; 5.07) | 0.904 | ||
| < 200 | 7 (77.8) | 2 (22.2) | 1 | |||
| 200–500 | 69 (86.3) | 11 (13.7) | 0.56 (0.10; 3.04) | 0.511 | ||
| > 500 | 187 (86.6) | 24 (11.4) | 0.45 (0.09; 2.29) | 0.335 | ||
| No | 229 (87.1) | 34 (12.9) | 1 | |||
| Yes | 34 (91.9) | 3 (8.1) | 0.59 (0.17; 2.04) | 0.409 | ||
| Clear | 243 (88.7) | 31 (11.3) | 1 | 1 | ||
| Cloud | 20 (76.9) | 6 (23.1) | 2.35 (0.88; 6.30) | 0.089 | 1.58 (0.51; 4.89) | 0.427 |
| Negative | 245 (88.4) | 32 (11.6) | 1 | |||
| Positive | 18 (78.3) | 5 (21.7) | 2.39 (0.82; 6.97) | 0.111 | ||
| Negative | 262 (88.8) | 33 (11.1) | 1 | 1 | ||
| Positive | 1 (20) | 4 (80) | 23.82 (2.41; 27.69) | 0.007 | 21.18(2.05; 218.86) | 0.01 |
| <20 | 191 (87.6) | 27 (12.4) | 1 | |||
| 20–1000 | 64 (87.7) | 9 (12.3) | 0.99(0.44; 2.23 | 0.991 | ||
| >1000 | 8 (88.9) | 1 (11.1) | 0.88(0.11; 7.35) | 0.909 | ||
Abbreviations: COR, crude odds ratio; AOR, adjusted odds ratio; ABU, asymptomatic bacteriuria.
Figure 1Microbiological profile of 37 isolates among 300 participants living with HIV attending CTC clinic at KCMC from July to September 2020.
Antimicrobial Susceptibility Pattern of 37 Bacterial Isolates Among 300 Participants Living with HIV Attending CTC Clinic at KCMC from July to September 2020
| Isolated Bacteria | Gen | Pip | Ceft | Amoxc | Amik | Clin | Nitr | Chlor | Vanc | TX | Cipro | Cefo | Pen | Ery |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| | NA | NA | NA | NA | NA | |||||||||
| Sensitive | 2 (50) | 5 (100) | 6 (100.0) | 1 (100) | 3 (100 | 4 (66.7) | 4 (66.7) | |||||||
| Resistant | 2 (50) | 0(0) | 0(0) | 0(0) | 0(0) | 2 (33.3) | 2 (33.3) | |||||||
| | NA | NA | NA | NA | ||||||||||
| Sensitive | 4 (100.0) | 1 (33.3) | 4 (100.0) | 4 (100.0) | 3 (100) | 1 (25.0) | 1 (100) | 1 (33.3) | ||||||
| Resistant | 0(0) | 2 (66.7) | 0(0) | 0(0) | 0(0) | 3 (75.0) | 2 (66.7) | 2 (100) | ||||||
| | NA | NA | NA | NA | ||||||||||
| Sensitive | 2 (100.0) | 1 (50.0) | 2 (100.0) | 2(100) | 2 (100.0) | |||||||||
| Resistant | 0(0) | 1 (50.0) | 0(0) | 0(0) | 1 (100) | 0(0) | 1 (100) | |||||||
| Total n(%) | ||||||||||||||
| S | 8(80) | 1(33.3) | 10(90.9) | 12(100) | 4(100) | NA | 6(66.7) | 1(100) | NA | 5(50) | 6(60) | NA | 1(100) | NA |
| R | 2(20) | 2(66.7) | 1(9.1) | 0(0) | 0(0) | NA | 3(33.3) | 0(0) | NA | 5(50) | 4(40) | NA | 0(0) | NA |
| | NA | NA | NA | |||||||||||
| Sensitive | 5 (100) | 4 (44.4 | 1 (16.7) | 6 (100) | 6 (54.5) | 3 (50) | 1 (50) | 2 (22.2) | ||||||
| Intermediate | 0(0) | 0(0) | 1 (16.7) | 1 (9.1) | ||||||||||
| Resistant | 0(0) | 5 (55.6) | 4 (66.7) | 1 (100) | 3 (27.3) | 3 (100) | 3 (50) | 1 (50) | 4 (100) | 7 (77.8) | ||||
| | NA | NA | NA | NA | NA | |||||||||
| Sensitive | 1 (100) | 1 (50.0) | 1 (100) | |||||||||||
| Intermediate | 1 (100) | |||||||||||||
| Resistant | 1 (50.0) | |||||||||||||
| | NA | |||||||||||||
| Sensitive | 3 (42.9) | 4 (66.7) | 1 (100) | 9 (81.8) | 4 (100) | 9 (75.0) | 1 (8.3) | 6 (54.5) | 3 (30) | |||||
| Intermediate | 1 (14.3 | 1 (100) | 1 (9.1) | 1 (8.3) | 2 (20) | |||||||||
| Resistant | 3 (42.9) | 2 (33.3) | 1 (100) | 1 (9.1) | 2 (16.7) | 2 (16.7) | 11 (91.7) | 1 (100) | 5 (45.5) | 5 (50) | ||||
| Total n(%) | NA | |||||||||||||
| S | 9(69.2) | 8(53.3) | 1(100) | 1(14.3) | 15(88.) | 4(80) | 15(68.2) | 1(14.3) | 4(22.2) | 1(33.3) | 6(37.5) | 6(30) | ||
| I | 1(7.7) | 0(0) | 0(0) | 1(14.3) | 1(5.9) | 0(0) | 2(9.1) | 0(0) | 0(0) | 0(0) | 1(6.3) | 2(10) | ||
| R | 3(23.1) | 7(46.7) | 0(0) | 5(71.4) | 1(5.9) | 1(20) | 5(22.7) | 6(85.7) | 14(77.8) | 2(66.7) | 9(56.2) | 12(60) |
Abbreviations: Gen, gentamycin; Pip, piperacillin; Ceft, ceftriaxone; amoxc, amoxicillin-clavulanic acid; amik, amikacin; clind, clindamycin; Nitr, nitrofurantoin; chlor, chloramphenicol; vanc, vancomycin; TX, trimethoprim-sulfamethoxazole; cipro, ciprofloxacin; cefo, cefotaxime; pen, penicillin; ery, erythromycin.
Multidrug Resistance Pattern Among Bacterial 37 Isolates from 300 People Living with HIV Attending CTC Clinic at KCMC from July to September 2020
| Total | MDR | |||||||
|---|---|---|---|---|---|---|---|---|
| Isolated Bacteria | n (%) | R0 | R1 | R2 | R3 | R4 | R5 | n (%) |
| 12 (32.4) | 4 | 1 | 4 | 2 | 1 | 3 (25.0) | ||
| | 6 (50.0) | 3 | 1 | 1 | 1 | 2 (16.7) | ||
| | 4 (33.3) | 1 | 3 | 0 (0.0) | ||||
| | 2 (16.7) | 1 | 1 | 1 (8.3) | ||||
| 25 (67.6) | 2 | 3 | 6 | 9 | 4 | 1 | 14 (56.0) | |
| | 11 (44.0) | 1 | 3 | 4 | 2 | 1 | 7 (28.0) | |
| | 2 (8.0) | 1 | 1 | 1 (4.0) | ||||
| | 12 (48.0) | 2 | 2 | 2 | 4 | 2 | 6 (24.0) | |
| Total | 37 (100.0) | 6 (16.2) | 4 (10.8) | 10 (27.1) | 11 (29.7) | 5 (13.5) | 1 (2.7) | 17 (45.9) |
Abbreviations: R0, no resistant drug reported; R1, resistance to one group of antibiotic; R2, resistance to two groups of antibiotics; R3, resistance to three groups of antibiotics; R4, resistance to four groups of antibiotics; R5, resistance to five groups of antibiotics; MDR, resistance to more than two groups of antibiotics.